Patents by Inventor Supriya PATEL

Supriya PATEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230391844
    Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
    Type: Application
    Filed: June 2, 2023
    Publication date: December 7, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Jiaxi WU, Supriya PATEL, Tong ZHANG, Nicolin BLOCH, Eric SMITH, Chia-Yang LIN, Vidur GARG, Erica ULLMAN
  • Publication number: 20230382969
    Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.
    Type: Application
    Filed: May 26, 2023
    Publication date: November 30, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Supriya PATEL, Tong ZHANG, Jiaxi WU, Aaron CHANG, Eric SMITH, Chia-Yang LIN, Samuel DAVIS
  • Publication number: 20230340105
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Application
    Filed: May 17, 2023
    Publication date: October 26, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
  • Publication number: 20230287117
    Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcy receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcy receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.
    Type: Application
    Filed: October 6, 2022
    Publication date: September 14, 2023
    Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
  • Patent number: 11708407
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: July 25, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chia-Yang Lin, Samuel Davis
  • Patent number: 11518807
    Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: December 6, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
  • Publication number: 20220235126
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Application
    Filed: February 7, 2022
    Publication date: July 28, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
  • Publication number: 20220195030
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Application
    Filed: February 7, 2022
    Publication date: June 23, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
  • Publication number: 20210246207
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Application
    Filed: March 30, 2021
    Publication date: August 12, 2021
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Patent number: 10988537
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 27, 2021
    Assignee: Regeneren Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Publication number: 20210040197
    Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.
    Type: Application
    Filed: August 7, 2020
    Publication date: February 11, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Tong Zhang, Erica Pyles, Michael Rosconi, Nina Liu, Supriya Patel, Eric Smith, Andrew Murphy, Chiayang Lin, Samuel Davis
  • Publication number: 20200109203
    Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 9, 2020
    Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
  • Patent number: 10556952
    Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: February 11, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
  • Publication number: 20180371090
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Application
    Filed: September 12, 2018
    Publication date: December 27, 2018
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Patent number: 10106610
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 23, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Publication number: 20180282411
    Abstract: The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc? receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc? receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.
    Type: Application
    Filed: March 30, 2016
    Publication date: October 4, 2018
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Tong Zhang, Supriya Patel
  • Publication number: 20160347839
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Application
    Filed: May 5, 2016
    Publication date: December 1, 2016
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Patent number: 9359437
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: June 7, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Publication number: 20140243504
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 28, 2014
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel DAVIS, Eric SMITH, Supriya PATEL